Multidrug resistance reversal in childhood malignancies—potential for a real step forward?
- 30 April 1996
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (4) , 641-644
- https://doi.org/10.1016/0959-8049(95)00663-x
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Clinical modulation of multidrug resistance in VAD-refractory multiple myelomaAnti-Cancer Drugs, 1994
- A phase I study of paclitaxel (taxol®) (T) in combination with SDZ PSC 833, a potent modulator of multidrug resistance (MDR)Anti-Cancer Drugs, 1994
- Clinical reversal of the multidrug resistance phenotype: True tumour modulation or pharmacokinetic interaction?European Journal Of Cancer, 1994
- Prognostic implication of immunodetection of P glycoprotein in Ewing's sarcomaZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Modulation of multidrug-resistant multiple myeloma by cyclosporinThe Lancet, 1992
- Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous systemJournal of Neurosurgery, 1992
- Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumorCancer Chemotherapy and Pharmacology, 1992
- Is the multidrug transporter a flippase?Trends in Biochemical Sciences, 1992
- P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for NeuroblastomaNew England Journal of Medicine, 1991
- Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenograftsBiochemical Pharmacology, 1989